Advanced Medical Solutions Group plc
(“AMS” or the “Group”)
Half Year Trading Update
~ Strong performance, integrations progressing well ~
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), a world-leading specialist in tissue-healing technologies, today announces a trading update for the six months ended 30 June 2025.
Strong underlying momentum in our core surgical product portfolio has continued to drive robust growth during the first half of the year. The integration of Peters Surgical and Syntacoll is progressing well with initial commercial synergies already contributing positively to surgical sales growth. As anticipated, the restructuring of Woundcare was successfully completed by the end of March, resulting in improved margins for that business from the second quarter.
The Group expects to report Half Year 2025 revenues of approximately £110 million (H1 2024: £68.0 million), and adjusted EBITDA of £24.0 – £24.5 million (H1 2024: £18.2 million). This performance remains in line with expectations and, underpinned by continued momentum in the business, the Board continues to be confident in meeting full-year consensus forecasts.
The Group expects to announce its interim results on 17 September 2025.
Chris Meredith, Chief Executive Officer of AMS, said: “One year on from successfully completing the acquisition of Peters Surgical, it is a good moment to take stock of the excellent integration progress to date, both operationally and in terms of strategic alignment. On the commercial front, we have been pleased to see early synergies already beginning to translate into top-line growth. We remain fully focused on delivering longer-term, significant synergies as integration continues. In parallel, our newly restructured Woundcare business has entered a new phase and is now making a steady contribution to the Group. Underpinned by our core surgical product portfolio, we are pressing ahead to deliver strong growth at the Group level.”